Stalevo in Early Wearing-Off Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG

Stalevo (levodopa/carbidopa/entacapone)

Oral, 50-150 mg levodopa four times daily, for up to 2 years

DRUG

Levodopa/carbidopa

Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years

Trial Locations (19)

8000

Århus Kommunehospital, Nørrebrogade 44

DK-9000 Aalborg

Aalborg Hospital, Aalborg

Unknown

Bispebjerg Hospital, Copenhagen

South Karelia Central Hospital, Lappeenranta

33521 Tampere

Tampere University Hospital, Tampere

61231 Bad Nauheim

Parkinson Klinik Bad Nauheim, Bad Nauheim

97616 Bad Neustadt

Neurologische Klinik Bad Neustadt, Bad Neustadt an der Saale

40225 Duesseldorf

Neurologische Klinik der Universitat Dusseldorf, Düsseldorf

21075 Hamburg

Allgemeines Krankenhaus Harburg, Hamburg

89073 Ulm

Praxis Drs Lang, Krauss, Schreiber, Ulm

Dublin 7

Mater Private Hospital, Dublin

SE-205 02

Universitetssjukhuset MAS, Malmo

SE-162 68

Läkarhuset Vällingby, Vällingby

KT16 0QA

Movement Disorder Services, Chertsey

CF14 4XW

University Hospital of Wales, Cardiff

Glan Clwyd Hospital, Rhyl

BS16 1LE

Frenchay Hospital, Bristol

WN7 1HS

Leigh Infirmary, Leigh

SO16 6YD

Southampton General Hospital, Southampton

All Listed Sponsors
lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT00125567 - Stalevo in Early Wearing-Off Patients | Biotech Hunter | Biotech Hunter